Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts
Author Department
Medicine
Document Type
Article, Peer-reviewed
Publication Date
11-2023
Abstract
Background: Carceral officials often cite diversion of medication for opioid use disorder (MOUD) (e.g., buprenorphine) as a reason for not offering MOUD treatment in jails and prisons with little understanding of patient perspectives. We aimed to understand patient perceptions of medication diversion from jail-based MOUD programs and the factors that contribute to and reduce diversion.
Methods: We conducted thematic analyses of semi-structured interviews held in 2021-22 with 38 adults who received MOUD treatment and were released from eight Massachusetts jails that had implemented a MOUD program on or after September 2019.
Results: Consistent with prior reports from carceral staff, patients perceived MOUD diversion to happen less frequently than expected, which they attributed to dosing protocols that have effectively reduced it. Patients reported that MOUD availability reduced the contraband buprenorphine market, although other contraband substances have entered jails (fentanyl, oxycodone, K2). Patients perceived Subutex to have greater misuse potential and added diversion risks. Patients valued graduated consequences and other efforts to reduce MOUD diversion and contraband for making jails safer and for enabling patients to receive treatment. Nearly all participants reported having heard about, witnessed, or been involved in actual or attempted diversion, with variation in reports by jail. Patients suggested that dispensing MOUD to all who need it immediately upon intake would be the most effective way to reduce MOUD diversion and contraband.
Conclusion: Formerly incarcerated patients perceived MOUD diversion within jail medication programs as occurring less often than expected and that it can be reduced with appropriate protocols. To help limit medication diversion, patients recommended provision of MOUD upon intake to all individuals with opioid use disorder who need it. Findings have implications for MOUD program adaptation, successful routinization, and diffusion in carceral settings.
Keywords: Buprenorphine; Carceral settings; Massachusetts Justice Community Opioid Innovation Network (MassJCOIN); Medication diversion; Medications for opioid use disorder (MOUD); Qualitative design.
Recommended Citation
Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Nov 17;122:104252. doi: 10.1016/j.drugpo.2023.104252. Epub ahead of print. PMID: 37980776.
PMID
37980776